Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

Administration of daclizumab, a humanized mAb directed against the IL-2Rα chain, strongly reduces brain inflammation in multiple sclerosis patients. Here we show that daclizumab treatment leads to only a mild functional blockade of CD4(+) T cells, the major candidate in multiple sclerosis pathogenes...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Bielekova, Bibiana, Catalfamo, Marta, Reichert-Scrivner, Susan, Packer, Amy, Cerna, Magdalena, Waldmann, Thomas A., McFarland, Henry, Henkart, Pierre A., Martin, Roland
Materialtyp: Artigo
Språk:Inglês
Publicerad: National Academy of Sciences 2006
Ämnen:
Biological Sciences
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC1458677/
https://ncbi.nlm.nih.gov/pubmed/16585503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0601335103
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk